

SEARCH REQUEST FORM

Scientific and Technical Information Center

Access DB# _____

Mailbox
12E12

Requester's Full Name: Anne-Marie Baker Examiner #: 74977 Date: 4/18/01
Art Unit: 1632 Phone Number 306-9155 Serial Number: 08/963,288
Mail Box and Bldg/Room Location: 12D07 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Expression Vector

Inventors (please provide full names): Norstedt et al

Earliest Priority Filing Date: 10/19/95

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

- Please perform an ~~all~~ search for

TTCTGAGAA

Limit to 12mer or smaller.

POINT OF CONTACT:

BARB O'BRYEN

TECH. INFORMATION SPECIALIST
STIC CM1 12C14 308-4291

- Claim is directed to an enhancer element consisting essentially of the nucleotide sequence.

- There is no CRF for this and thus no SEQ ID No. for this 9-nucleotide sequence because the sequence rules apply to sequences 10-nucleotides or longer. Thus, this case is not required to comply with the sequence rules. Or, looked at another way, the case is in compliance because no CRF is required.

STAFF USE ONLY

Type of Search Vendors and cost where applicable

Searcher: <u>BAB</u>	NA Sequence (#) <u>1</u>	STN _____
Searcher Phone #:	AA Sequence (#) _____	Dialog _____
Searcher Location:	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>4-18-01</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>4-23-01</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>20</u>	Fulltext _____	Sequence Systems <u>IG, Et alias 03</u>
Clerical Prep Time:	Patent Family _____	WWW/Internet _____
Online Time: <u>15</u>	Other _____	Other (specify) _____

THIS PAGE BLANK (USPTO)

QY 1 ttctggaaa 9
 ||||||| 1
 US-08-369-796-34/C
 Db 9 TTCTGAGAA 1

RESULT 2
 US-08-369-796-34/C
 Sequence 34, Application US/08369796
 Patent No. 571622

GENERAL INFORMATION:
 APPLICANT: James E. Darnell, Jr.
 APPLICANT: Zilong Wen
 APPLICANT: Curt M. Horvath
 APPLICANT: Zhong Zhong

TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS

NUMBER OF SEQUENCES: 39

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Klauber & Jackson
 STREET: 411 Hackensack Avenue
 CITY: Hackensack
 STATE: New Jersey
 COUNTRY: USA
 ZIP: 07601

COMPUTER READABLE FORM:
 COMPUTER TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US 08/228, 935
 FILING DATE: 27-MAR-1995
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/410,779B
 FILING DATE: 14-APR-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: JURGENSEN, THOMAS E
 REGISTRATION NUMBER: 34 195
 REFERENCE/DOCKET NUMBER: 016-0013A.US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 550-7675
 TELEFAX: (619) 531-3906

INFORMATION FOR SEQ ID NO: 35:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single

TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 DESCRIPTION: />desc = "OTHER NUCLEIC ACID,"
 DESCRIPTION: SYNTHETIC DNA,

US-08-410-779B-35

Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07; Mismatches 0; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ttctggaaa 9
 Db 9 TTCTGAGAA 1

RESULT 4
 US-08-852-091-34/C
 Sequence 34, Application US/08852091
 Patent No. 5803228

GENERAL INFORMATION:
 APPLICANT: James E. Darnell, Jr.
 APPLICANT: Zilong Wen
 APPLICANT: Curt M. Horvath
 APPLICANT: Zhong Zhong

TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS

NUMBER OF SEQUENCES: 39

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Klauber & Jackson
 STREET: 411 Hackensack Avenue
 CITY: Hackensack
 STATE: New Jersey
 COUNTRY: USA
 ZIP: 07601

COMPUTER READABLE FORM:
 COMPUTER TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/852,091
 FILING DATE: 06-MAY-1997

ADDRESSEE: LIGAND PHARMACEUTICALS INCORPORATED
 STREET: 9393 TOWNE CENTRE DRIVE
 CITY: SAN DIEGO
 STATE: CALIFORNIA
 COUNTRY: US
 ZIP: 92121

COMPUTER READABLE FORM:
 COMPUTER TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US 08/228, 935
 FILING DATE: 27-MAR-1995
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/410,779B
 FILING DATE: 14-APR-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: JURGENSEN, THOMAS E
 REGISTRATION NUMBER: 34 195
 REFERENCE/DOCKET NUMBER: 016-0013A.US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 550-7675
 TELEFAX: (619) 531-3906

INFORMATION FOR SEQ ID NO: 35:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single

TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 DESCRIPTION: />desc = "OTHER NUCLEIC ACID,"
 DESCRIPTION: SYNTHETIC DNA,

US-08-410-779B-35

Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07; Mismatches 0; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ttctggaaa 9
 Db 9 TTCTGAGAA 1

RESULT 3
 US-08-410-779B-35/C
 Sequence 35, Application US/08410779B

GENERAL INFORMATION:
 APPLICANT: SEIDEL, H. MARTI
 APPLICANT: LAMB, I. PETER
 TITLE OF INVENTION: DNA SPACER REGULATORY ELEMENTS

NUMBER OF SEQUENCES: 166

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Klauber & Jackson
 STREET: 411 Hackensack Avenue
 CITY: Hackensack
 STATE: New Jersey
 COUNTRY: USA
 ZIP: 07601

COMPUTER READABLE FORM:
 COMPUTER TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/852,091
 FILING DATE: 06-MAY-1997

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

On nucleic - nucleic search, using sw model

Run on: April 21, 2001, 12:13:27 ; Search time 80.36 Seconds

(without alignments)
19.555 Million cell updates/sec

Title: SHORT
perfect score: 9
Sequence: 1 ttctgagaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 302621 seqs, 87301344 residues

Total number of hits satisfying chosen parameters: 23618

Minimum DB seq length: 0

Maximum DB seq length: 12

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents NA:
1: /cggn2_6/ptodata/2/ina/5A_COMB.seq: *
2: /cggn2_6/ptodata/2/ina/5B_COMB.seq: *
3: /cggn2_6/ptodata/2/ina/6A_COMB.seq: *
4: /cggn2_6/ptodata/2/ina/6B_COMB.seq: *
5: /cggn2_6/ptodata/2/ina/PCTUS.COMB.seq: *
6: /cggn2_6/ptodata/2/ina/backfiles.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
c 1	9	1	US-08-411-020-13		Sequence 13, Appl
c 2	9	100.0	9	1	Sequence 13, Appl
c 3	9	100.0	9	1	US-08-411-020-13
c 4	9	100.0	9	1	US-08-410-798-35
c 5	9	100.0	9	2	US-08-852-091-34
c 6	9	100.0	9	5	PCT-US95-0477-35
c 7	8	88.9	10	1	PCT-US95-17025-34
c 8	8	88.9	10	1	US-08-440-7878-85
c 9	7.4	82.2	9	1	US-08-268-799-3
c 10	7.4	82.2	9	1	US-08-411-020-12
c 11	7.4	82.2	9	1	US-08-411-020-12
c 12	7.4	82.2	9	1	US-08-411-020-13
c 13	7.4	82.2	9	1	US-08-369-796-31
c 14	7.4	82.2	9	1	US-08-410-7788-51
c 15	7.4	82.2	9	1	US-08-369-796-36
c 16	7.4	82.2	9	1	US-08-369-796-38
c 17	7.4	82.2	9	1	US-08-410-7788-31
c 18	7.4	82.2	9	1	US-08-410-7788-35
c 19	7.4	82.2	9	1	US-08-410-7788-51
c 20	7.4	82.2	9	1	US-08-410-7788-51
c 21	7.4	82.2	9	2	US-08-852-091-31
c 22	7.4	82.2	9	2	US-08-852-091-34
c 23	7.4	82.2	9	2	US-08-852-091-36
c 24	7.4	82.2	9	2	US-08-852-091-38
c 25	7.4	82.2	9	3	US-08-873-709-6
c 26	7.4	82.2	9	5	PCT-US95-04477-31
c 27	7.4	82.2	9	5	PCT-US95-04477-35

ALIGNMENTS

RESULT	1	US-08-411-020-13/C
;	Sequence 13, Appl	Patent No. 571209
;	GENERAL INFORMATION:	APPLICANT: SEIDEL, H. MARTI
;	;	APPLICANT: LAMB, I. PETER
;	;	APPLICANT: CHAN, SHIN SHAY TIAN
;	;	TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR DETECTING MODULATORS OF CYTOKINE ACTION
;	;	NUMBER OF SEQUENCES: 59
;	;	CORRESPONDENCE ADDRESS:
;	;	ADDRESSEE: Ligand Pharmaceuticals Incorporated
;	;	STREET: 9939 Towne Centre Drive
;	;	CITY: San Diego
;	;	STATE: California
;	;	COUNTRY: US
;	;	ZIP: 92121
;	;	COMPUTER READABLE FORM:
;	;	MEDIUM TYPE: Floppy disk
;	;	COMPUTER: IBM PC compatible
;	;	OPERATING SYSTEM: PC-DOS/MS-DOS
;	;	SOFTWARE: Patentin Release #1.0, Version #1.30
;	;	CURRENT APPLICATION DATA:
;	;	APPLICATION NUMBER: US/08/411,020
;	;	FILING DATE: 27-MAR-1995
;	;	CLASSIFICATION: 435
;	;	ATTORNEY/AGENCY INFORMATION:
;	;	NAME: Jurgenssen, Thomas E.
;	;	REGISTRATION NUMBER: 34,195
;	;	REFERENCE/DOCKET NUMBER: 016-0030.US
;	;	TELECOMMUNICATION INFORMATION:
;	;	TELEPHONE: (619) 535-3967
;	;	TELEFAX: (619) 535-3966
;	;	INFORMATION FOR SEQ ID NO: 13:
;	;	SEQUENCE CHARACTERISTICS:
;	;	SEQUENCE LENGTH: 9 base pairs
;	;	TYPE: nucleic acid
;	;	STRANDEDNESS: single
;	;	TOPOLogy: linear
;	;	MOLECULE TYPE: other nucleic acid
;	;	DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
;	;	DESCRIPTION: SYNTHETIC DNA,"
;	;	US-08-411-020-13

Query Match	100.0%	Score	9	DB 1	Length	9
Sequence 34, Appl	100.0%	Score	9	DB 1	Length	9
Sequence 36, Appl	100.0%	Score	9	DB 1	Length	9
Sequence 38, Appl	100.0%	Score	9	DB 1	Length	9
Sequence 6, Appl	100.0%	Score	9	DB 1	Length	9
Sequence 31, Appl	100.0%	Score	9	DB 1	Length	9
Sequence 35, Appl	100.0%	Score	9	DB 1	Length	9

Sequence 51, Appl	Sequence 51, Appl
Sequence 53, Appl	Sequence 53, Appl
Sequence 54, Appl	Sequence 54, Appl
Sequence 55, Appl	Sequence 55, Appl
Sequence 56, Appl	Sequence 56, Appl
Sequence 8, Appl	Sequence 8, Appl
Sequence 410, Appl	Sequence 410, Appl
Sequence 17, Appl	Sequence 17, Appl
Sequence 8, Appl	Sequence 8, Appl
Sequence 516, Appl	Sequence 516, Appl
Sequence 517, Appl	Sequence 517, Appl
Sequence 518, Appl	Sequence 518, Appl
Sequence 519, Appl	Sequence 519, Appl
Sequence 520, Appl	Sequence 520, Appl
Sequence 521, Appl	Sequence 521, Appl
Sequence 522, Appl	Sequence 522, Appl
Sequence 523, Appl	Sequence 523, Appl
Sequence 524, Appl	Sequence 524, Appl
Sequence 525, Appl	Sequence 525, Appl
Sequence 526, Appl	Sequence 526, Appl
Sequence 527, Appl	Sequence 527, Appl
Sequence 528, Appl	Sequence 528, Appl
Sequence 529, Appl	Sequence 529, Appl
Sequence 530, Appl	Sequence 530, Appl
Sequence 531, Appl	Sequence 531, Appl
Sequence 532, Appl	Sequence 532, Appl
Sequence 533, Appl	Sequence 533, Appl
Sequence 534, Appl	Sequence 534, Appl
Sequence 535, Appl	Sequence 535, Appl
Sequence 536, Appl	Sequence 536, Appl
Sequence 537, Appl	Sequence 537, Appl
Sequence 538, Appl	Sequence 538, Appl
Sequence 539, Appl	Sequence 539, Appl
Sequence 540, Appl	Sequence 540, Appl
Sequence 541, Appl	Sequence 541, Appl
Sequence 542, Appl	Sequence 542, Appl
Sequence 543, Appl	Sequence 543, Appl
Sequence 544, Appl	Sequence 544, Appl
Sequence 545, Appl	Sequence 545, Appl
Sequence 546, Appl	Sequence 546, Appl
Sequence 547, Appl	Sequence 547, Appl
Sequence 548, Appl	Sequence 548, Appl
Sequence 549, Appl	Sequence 549, Appl
Sequence 550, Appl	Sequence 550, Appl
Sequence 551, Appl	Sequence 551, Appl
Sequence 552, Appl	Sequence 552, Appl
Sequence 553, Appl	Sequence 553, Appl
Sequence 554, Appl	Sequence 554, Appl
Sequence 555, Appl	Sequence 555, Appl
Sequence 556, Appl	Sequence 556, Appl
Sequence 557, Appl	Sequence 557, Appl
Sequence 558, Appl	Sequence 558, Appl
Sequence 559, Appl	Sequence 559, Appl
Sequence 560, Appl	Sequence 560, Appl
Sequence 561, Appl	Sequence 561, Appl
Sequence 562, Appl	Sequence 562, Appl
Sequence 563, Appl	Sequence 563, Appl
Sequence 564, Appl	Sequence 564, Appl
Sequence 565, Appl	Sequence 565, Appl
Sequence 566, Appl	Sequence 566, Appl
Sequence 567, Appl	Sequence 567, Appl
Sequence 568, Appl	Sequence 568, Appl
Sequence 569, Appl	Sequence 569, Appl
Sequence 570, Appl	Sequence 570, Appl
Sequence 571, Appl	Sequence 571, Appl
Sequence 572, Appl	Sequence 572, Appl
Sequence 573, Appl	Sequence 573, Appl
Sequence 574, Appl	Sequence 574, Appl
Sequence 575, Appl	Sequence 575, Appl
Sequence 576, Appl	Sequence 576, Appl
Sequence 577, Appl	Sequence 577, Appl
Sequence 578, Appl	Sequence 578, Appl
Sequence 579, Appl	Sequence 579, Appl
Sequence 580, Appl	Sequence 580, Appl
Sequence 581, Appl	Sequence 581, Appl
Sequence 582, Appl	Sequence 582, Appl
Sequence 583, Appl	Sequence 583, Appl
Sequence 584, Appl	Sequence 584, Appl
Sequence 585, Appl	Sequence 585, Appl
Sequence 586, Appl	Sequence 586, Appl
Sequence 587, Appl	Sequence 587, Appl
Sequence 588, Appl	Sequence 588, Appl
Sequence 589, Appl	Sequence 589, Appl
Sequence 590, Appl	Sequence 590, Appl
Sequence 591, Appl	Sequence 591, Appl
Sequence 592, Appl	Sequence 592, Appl
Sequence 593, Appl	Sequence 593, Appl
Sequence 594, Appl	Sequence 594, Appl
Sequence 595, Appl	Sequence 595, Appl
Sequence 596, Appl	Sequence 596, Appl
Sequence 597, Appl	Sequence 597, Appl
Sequence 598, Appl	Sequence 598, Appl
Sequence 599, Appl	Sequence 599, Appl
Sequence 600, Appl	Sequence 600, Appl
Sequence 601, Appl	Sequence 601, Appl
Sequence 602, Appl	Sequence 602, Appl
Sequence 603, Appl	Sequence 603, Appl
Sequence 604, Appl	Sequence 604, Appl
Sequence 605, Appl	Sequence 605, Appl
Sequence 606, Appl	Sequence 606, Appl
Sequence 607, Appl	Sequence 607, Appl
Sequence 608, Appl	Sequence 608, Appl
Sequence 609, Appl	Sequence 609, Appl
Sequence 610, Appl	Sequence 610, Appl
Sequence 611, Appl	Sequence 611, Appl
Sequence 612, Appl	Sequence 612, Appl
Sequence 613, Appl	Sequence 613, Appl
Sequence 614, Appl	Sequence 614, Appl
Sequence 615, Appl	Sequence 615, Appl
Sequence 616, Appl	Sequence 616, Appl
Sequence 617, Appl	Sequence 617, Appl
Sequence 618, Appl	Sequence 618, Appl
Sequence 619, Appl	Sequence 619, Appl
Sequence 620, Appl	Sequence 620, Appl
Sequence 621, Appl	Sequence 621, Appl
Sequence 622, Appl	Sequence 622, Appl
Sequence 623, Appl	Sequence 623, Appl
Sequence 624, Appl	Sequence 624, Appl
Sequence 625, Appl	Sequence 625, Appl
Sequence 626, Appl	Sequence 626, Appl
Sequence 627, Appl	Sequence 627, Appl
Sequence 628, Appl	Sequence 628, Appl
Sequence 629, Appl	Sequence 629, Appl
Sequence 630, Appl	Sequence 630, Appl
Sequence 631, Appl	Sequence 631, Appl
Sequence 632, Appl	Sequence 632, Appl
Sequence 633, Appl	Sequence 633, Appl
Sequence 634, Appl	Sequence 634, Appl
Sequence 635, Appl	Sequence 635, Appl
Sequence 636, Appl	Sequence 636, Appl
Sequence 637, Appl	Sequence 637, Appl
Sequence 638, Appl	Sequence 638, Appl
Sequence 639, Appl	Sequence 639, Appl
Sequence 640, Appl	Sequence 640, Appl
Sequence 641, Appl	Sequence 641, Appl
Sequence 642, Appl	Sequence 642, Appl
Sequence 643, Appl	Sequence 643, Appl
Sequence 644, Appl	Sequence 644, Appl
Sequence 645, Appl	Sequence 645, Appl
Sequence 646, Appl	Sequence 646, Appl
Sequence 647, Appl	Sequence 647, Appl
Sequence 648, Appl	Sequence 648, Appl
Sequence 649, Appl	Sequence 649, Appl
Sequence 650, Appl	Sequence 650, Appl
Sequence 651, Appl	Sequence 651, Appl
Sequence 652, Appl	Sequence 652, Appl
Sequence 653, Appl	Sequence 653, Appl
Sequence 654, Appl	Sequence 654, Appl
Sequence 655, Appl	Sequence 655, Appl
Sequence 656, Appl	Sequence 656, Appl
Sequence 657, Appl	Sequence 657, Appl
Sequence 658, Appl	Sequence 658, Appl
Sequence 659, Appl	Sequence 659, Appl
Sequence 660, Appl	Sequence 660, Appl
Sequence 661, Appl	Sequence 661, Appl
Sequence 662, Appl	Sequence 662, Appl
Sequence 663, Appl	Sequence 663, Appl
Sequence 664, Appl	Sequence 664, Appl
Sequence 665, Appl	Sequence 665, Appl
Sequence 666, Appl	Sequence 666, Appl
Sequence 667, Appl	Sequence 667, Appl
Sequence 668, Appl	Sequence 668, Appl
Sequence 669, Appl	Sequence 669, Appl
Sequence 670, Appl	Sequence 670, Appl
Sequence 671, Appl	Sequence 671, Appl
Sequence 672, Appl	Sequence 672, Appl
Sequence 673, Appl	Sequence 673, Appl
Sequence 674, Appl	Sequence 674, Appl
Sequence 675, Appl	Sequence 675, Appl
Sequence 676, Appl	Sequence 676, Appl
Sequence 677, Appl	Sequence 677, Appl
Sequence 678, Appl	Sequence 678, Appl
Sequence 679, Appl	Sequence 679, Appl
Sequence 680, Appl	Sequence 680, Appl
Sequence 681, Appl	Sequence 681, Appl
Sequence 682, Appl	Sequence 682, Appl
Sequence 683, Appl	Sequence 683, Appl
Sequence 684, Appl	Sequence 684, Appl
Sequence 685, Appl	Sequence 685, Appl
Sequence 686, Appl	Sequence 686, Appl
Sequence 687, Appl	Sequence 687, Appl
Sequence 688, Appl	Sequence 688, Appl
Sequence 689, Appl	Sequence 689, Appl
Sequence 690, Appl	Sequence 690, Appl
Sequence 691, Appl	Sequence 691, Appl
Sequence 692, Appl	Sequence 692, Appl
Sequence 693, Appl	Sequence 693, Appl
Sequence 694, Appl	Sequence 694, Appl
Sequence 695, Appl	Sequence 695, Appl
Sequence 696, Appl	Sequence 696, Appl
Sequence 697, Appl	Sequence 697, Appl
Sequence 698, Appl	Sequence 698, Appl
Sequence 699, Appl	Sequence 699, Appl
Sequence 700, Appl	Sequence 700, Appl
Sequence 701, Appl	Sequence 701, Appl
Sequence 702, Appl	Sequence 702, Appl
Sequence 703, Appl	Sequence 703, Appl
Sequence 704, Appl	Sequence 704, Appl
Sequence 705, Appl	Sequence 705, Appl
Sequence 706, Appl	Sequence 706, Appl
Sequence 707, Appl	Sequence 707, Appl
Sequence 708, Appl	Sequence 708, Appl
Sequence 709, Appl	Sequence 709, Appl
Sequence 710, Appl	Sequence 710, Appl
Sequence 711, Appl	Sequence 711, Appl
Sequence 712, Appl	Sequence 712, Appl
Sequence 713, Appl	Sequence 713, Appl
Sequence 714, Appl	Sequence 714, Appl
Sequence 715, Appl	Sequence 715, Appl
Sequence 716, Appl	Sequence 716, Appl
Sequence 717, Appl	Sequence 717, Appl
Sequence 718, Appl	Sequence 718, Appl
Sequence 719, Appl	Sequence 719, Appl
Sequence 720, Appl	Sequence 720, Appl
Sequence 721, Appl	Sequence 721, Appl
Sequence 722, Appl	Sequence 722, Appl
Sequence 723, Appl	Sequence 723, Appl
Sequence 724, Appl	Sequence 724, Appl
Sequence 725, Appl	Sequence 725, Appl
Sequence 726, Appl	Sequence 726, Appl
Sequence 727, Appl	Sequence 727, Appl
Sequence 728, Appl	Sequence 728, Appl
Sequence 729, Appl	Sequence 729, Appl
Sequence 730, Appl	Sequence 730, Appl
Sequence 731, Appl	Sequence 731, Appl
Sequence 732, Appl	Sequence 732, Appl
Sequence 733, Appl	Sequence 733, Appl
Sequence 734, Appl	Sequence 734, Appl
Sequence 735, Appl	Sequence 735, Appl
Sequence 736, Appl	Sequence 736, Appl
Sequence 737, Appl	Sequence 737, Appl
Sequence 738, Appl	Sequence 738, Appl
Sequence 739, Appl	Sequence 739, Appl
Sequence 740, Appl	Sequence 740, Appl
Sequence 741, Appl	Sequence 741, Appl
Sequence 742, Appl	Sequence 742, Appl
Sequence 743, Appl	Sequence 743, Appl
Sequence 744, Appl	Sequence 744, Appl
Sequence 745, Appl	Sequence 745, Appl
Sequence 746, Appl	Sequence 746, Appl
Sequence 747, Appl	Sequence 747, Appl
Sequence 748, Appl	Sequence 748, Appl
Sequence 749, Appl	Sequence 749, Appl
Sequence 750, Appl	Sequence 750, Appl
Sequence 751, Appl	Sequence 751, Appl
Sequence 752, Appl	Sequence 752, Appl
Sequence 753, Appl	Sequence 753, Appl

QY 1 ttctggaaaa 9
 |||||
 9 TTCTGGAGAA 1

RESULT 2
 US-08-369-796-34/c
 Sequence 34, Application US/08369796
 Patent No. 5716622
 GENERAL INFORMATION:
 APPLICANT: James E. Darnell, Jr.
 APPLICANT: Zilong Wen
 APPLICANT: Curt M. Horvath
 APPLICANT: Zhong Zhong
 TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL PROTEINS
 NUMBER OF SEQUENCES: 39
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Klauber & Jackson
 STREET: 411 Hackensack Avenue
 CITY: Hackensack
 STATE: New Jersey
 COUNTRY: USA
 ZIP: 07601

COMPUTER READABLE FORM:
 COMPUTER TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US 08/228, 935
 FILING DATE: 14-APR-1994
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Jackson Esq., David A.
 REGISTRATION NUMBER: 26,742
 REFERENCE/DOCKET NUMBER: 600-1-116
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 201 487-5800
 TELEX: 133521
 INFORMATION FOR SEQ ID NO: 34:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
 US-08-410-779B-35

RESULT 3
 Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ttctggaaaa 9
 Db 9 TTCTGGAGAA 1

RESULT 4
 Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ttctggaaaa 9
 Db 9 TTCTGGAGAA 1

RESULT 3
 US-08-410-779B-35/c
 Sequence 35, Application US/08410779B
 Patent No. 583228
 GENERAL INFORMATION:
 APPLICANT: Seidel, H. Marti
 APPLICANT: LAMB, I. Peter
 TITLE OF INVENTION: DNA SPACER REGULATORY ELEMENTS
 TITLE OF INVENTION: RESPONSIVE TO CYTOKINES AND METHODS FOR THEIR USE
 NUMBER OF SEQUENCES: 166
 CORRESPONDENCE ADDRESS:

ADDRESSEE: LIGAND PHARMACEUTICALS INCORPORATED
 STREET: 9393 TOWNE CENTRE DRIVE
 CITY: SAN DIEGO
 STATE: CALIFORNIA
 COUNTRY: US
 ZIP: 92121

COMPUTER READABLE FORM:
 COMPUTER TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US 08/410,779B
 FILING DATE: 27-MAR-1995
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 08/228, 935
 ATTORNEY/AGENT INFORMATION:
 NAME: JURGENSEN, THOMAS E
 REGISTRATION NUMBER: 34,195
 REFERENCE/DOCKET NUMBER: 016-0013A.US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 550-7675
 TELEFAX: (619) 535-3905
 INFORMATION FOR SEQ ID NO: 35:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
 US-08-410-779B-35

RESULT 4
 Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ttctggaaaa 9
 Db 9 TTCTGGAGAA 1

RESULT 4
 Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ttctggaaaa 9
 Db 9 TTCTGGAGAA 1

RESULT 4
 Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ttctggaaaa 9
 Db 9 TTCTGGAGAA 1

RESULT 4
 Query Match 100.0%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CLASSIFICATION: 424
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/369,796
 FILING DATE: 06-JAN-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Jackson Esq., David A.
 REGISTRATION NUMBER: 26,742
 REFERENCE/DOCKET NUMBER: 600-1-116
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 201 487-5800
 TELEX: 133521
 INFORMATION FOR SEQ ID NO: 34:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: DNA synthetic probe
 HYPOTHETICAL: NO
 US-08-852-091-34

Query Match 100.0%; Score 9; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 ttcttagaa 9
 Db 9 TTCTGAGAA 1

RESULT 5
 PCT-US95-04477-35/c
 Sequence 35, Application PC/US9504477

GENERAL INFORMATION:
 APPLICANT: ;
 TITLE OF INVENTION: DNA SPACER REGULATORY ELEMENTS RESPONSIVE TO CYTOKINES AND METHODS FOR THEIR USE
 NUMBER OF SEQUENCES: 165
 COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/17025
 FILING DATE: 28-DEC-1995
 CLASSIFICATION:

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/369,796
 FILING DATE: 06-JAN-1995
 CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:
 NAME: Jackson Esq., David A.
 REGISTRATION NUMBER: 26,742
 REFERENCE/DOCKET NUMBER: 600-1-116
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 201 487-5800
 TELEX: 133521
 INFORMATION FOR SEQ ID NO: 34:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: DNA synthetic probe
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 PCT-US95-17025-34

Query Match 100.0%; Score 9; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.9e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 ttcttagaa 9
 Db 9 TTCTGAGAA 1

RESULT 7
 US-08-440-787A-85/c
 Sequence 85, Application US/08440787A
 PATENT NO. 577034

GENERAL INFORMATION:
 APPLICANT: Huie, William D.
 TITLE OF INVENTION: Soluble Peptides Having Constrained, Secondary Conformation in Solution and Method of Making
 TITLE OF INVENTION: Same.
 NUMBER OF SEQUENCES: 174

RESPONSE ADDRESS:
 ADDRESSEE: Campbell & Flores LLP

STREET: 4370 La Jolla Village Drive, Suite 700
 CITY: San Diego
 STATE: California
 COUNTRY: USA
 ZIP: 92122

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/440.787A
 FILING DATE: 15-MAY-1995
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 07/978,893
 FILING DATE: 10-NOV-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Campbell, Cathryn A.
 REGISTRATION NUMBER: 31.815
 REFERENCE/DOCKET NUMBER: P-IX 1586
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 535-8949
 TELEFAX: (619) 535-8949
 REFERENCE/DOCKET NUMBER: P-IX 1586
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 535-9001
 TELEX: (619) 535-8949
 INFORMATION FOR SEQ ID NO: 85:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 10 base pairs
 STRANDEDNESS: single
 TOPOLOGY: linear

US-08-440-787A-85

RESULT 8

Query Match 88.9%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 3.6e+03;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 tctgaga 9
 |||||
 Db 10 TCTGAGAA 3

Query Match 88.9%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 3.6e+03;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ttctgaga 8
 |||||
 Db 3 TTCTGAGA 10

RESULT 9

Query Match 88.9%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 3.6e+03;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ttctgaga 8

US-08-08-440-787A-85

Sequence 86, Application US/08440787A
 Patent No. 5770434

GENERAL INFORMATION:

APPLICANT: Huse, William D.

TITLE OF INVENTION: Soluble Peptides Having Constrained, Secondary Conformation in Solution and Method of Making

TITLE OF INVENTION: Secondary Conformation in Solution and Method of Making

TITLE OF INVENTION: Same.

NUMBER OF SEQUENCES: 174

CORRESPONDENCE ADDRESS:

ADDRESSEE: Campbell & Flores LLP
 STREET: 4370 La Jolla Village Drive, Suite 700
 CITY: San Diego
 STATE: California
 COUNTRY: USA
 ZIP: 92122

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/268,799
 FILING DATE: 22-MAY-1992
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 07/887,505
 FILING DATE: 15-MAY-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Elisenstein, Ronald I.
 REGISTRATION NUMBER: 30528
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 522-3400
 TELEX: 20021 stte ur
 INFORMATION FOR SEQ ID NO: 3:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 STRANDEDNESS: unknown
 TOPOLOGY: unknown

US-08-268-799-3

Query Match 88.9%; Score 7.4; DB 1; Length 9;
 Best Local Similarity 88.9%; Pred. No. 1.9e+07;

NAME: Campbell, Cathryn A.

Matches	8;	Conservative	0;	Mismatches	1;	Indels	0;	Gaps	0;
Qy	1	ttctgagaa	9						
Db	9	TTCAGAA	1						
RESULT 10									
US-08-411-020-12									
; Sequence 12; Application US/08411020									
; Patent No. 5712094									
; GENERAL INFORMATION:									
; APPLICANT: SEIDEL, H. MARTI									
; APPLICANT: LAMB, T. PETER									
; APPLICANT: CHAN, SHIN-SHAY TIAN									
; TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR									
; DETECTING MODULATORS OF CYTOKINE ACTION									
; NUMBER OF SEQUENCES: 59									
; CORRESPONDENCE ADDRESS:									
; ADDRESSEE: Ligand Pharmaceuticals Incorporated									
; STREET: 9393 Towne Centre Drive									
; CITY: San Diego									
; STATE: California									
; COUNTRY: US									
; ZIP: 92121									
; COMPUTER READABLE FORM:									
; MEDIUM TYPE: Floppy disk									
; COMPUTER: IBM PC compatible									
; OPERATING SYSTEM: PC-DOS/MS-DOS									
; SOFTWARE: PatentIn Release #1.0, Version #1.30									
; CURRENT APPLICATION DATA:									
; APPLICATION NUMBER: US/08/411,020									
; FILING DATE: 27-MAR-1995									
; CLASSIFICATION: 435									
; ATTORNEY/AGENT INFORMATION:									
; NAME: Jurgensen, Thomas E.									
; REGISTRATION NUMBER: 34,195									
; REFERENCE/DOCKET NUMBER: 016-0030.US									
; TELECOMMUNICATION INFORMATION:									
; TELEPHONE: (619) 550-7675									
; TELEFAX: (619) 537-3906									
; INFORMATION FOR SEQ ID NO: 12:									
; SEQUENCE CHARACTERISTICS:									
; LENGTH: 9 base pairs									
; TYPE: nucleic acid									
; STRANDEDNESS: single									
; TOPOLOGY: linear									
; MOLECULE TYPE: other nucleic acid									
; DESCRIPTION: /desc = "OTHER NUCLEIC ACID,									
; SYNTHETIC DNA"									
; US-08-411-020-12									
ATTORNEY/AGENT INFORMATION:									
NAME: Jurgensen, Thomas E.									
REGISTRATION NUMBER: 34,195									
REFERENCE/DOCKET NUMBER: 016-0030.US									
TELECOMMUNICATION INFORMATION:									
TELEPHONE: (619) 550-7675									
TELEFAX: (619) 537-3906									
INFORMATION FOR SEQ ID NO: 12:									
SEQUENCE CHARACTERISTICS:									
LENGTH: 9 base pairs									
TYPE: nucleic acid									
STRANDEDNESS: single									
TOPOLOGY: linear									
MOLECULE TYPE: other nucleic acid									
DESCRIPTION: /desc = "OTHER NUCLEIC ACID,									
SYNTHETIC DNA"									
US-08-411-020-12									
RESULT 12									
US-08-411-020-13									
; Sequence 13; Application US/08411020									
; Patent No. 5712094									
; GENERAL INFORMATION:									
; APPLICANT: SEIDEL, H. MARTI									
; APPLICANT: LAMB, T. PETER									
; APPLICANT: CHAN, SHIN-SHAY TIAN									
; TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR									
; DETECTING MODULATORS OF CYTOKINE ACTION									
; NUMBER OF SEQUENCES: 59									
; CORRESPONDENCE ADDRESS:									
; ADDRESSEE: Ligand Pharmaceuticals Incorporated									
; STREET: 9393 Towne Centre Drive									
; CITY: San Diego									
; STATE: California									
; COUNTRY: US									
; ZIP: 92121									
; COMPUTER READABLE FORM:									
; MEDIUM TYPE: Floppy disk									
; COMPUTER: IBM PC compatible									
; OPERATING SYSTEM: PC-DOS/MS-DOS									
; SOFTWARE: PatentIn Release #1.0, Version #1.30									
; CURRENT APPLICATION DATA:									
; APPLICATION NUMBER: US/08/411,020									
; FILING DATE: 27-MAR-1995									
; CLASSIFICATION: 435									
; ATTORNEY/AGENT INFORMATION:									
; NAME: Jurgensen, Thomas E.									

REGISTRATION NUMBER: 34,195
 REFERENCE/DOCKET NUMBER: 016-0030.US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 550-7675
 TELEFAX: (619) 535-3906

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid
 DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
 SYNTHETIC DNA,"
 ; US-08-411-020-13

RESULT 13
 US-08-369-796-31/C
 ; Sequence 31, Application US/08369796
 ; Patent No. 5716622

GENERAL INFORMATION:

APPLICANT: James E. Darnell, Jr.
 APPLICANT: Zilong Wen
 APPLICANT: Curt M. Horvath
 APPLICANT: Zhong Zhong

TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL NUMBER OF SEQUENCES: 39

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Klauber & Jackson
 STREET: 411 Hackensack Avenue
 CITY: Hackensack
 STATE: New Jersey
 COUNTRY: USA
 ZIP: 07601

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/369-796
 FILING DATE: 06-JAN-1995
 CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
 NAME: Jackson Esq., David A.
 REGISTRATION NUMBER: 26,742
 REFERENCE/DOCKET NUMBER: 600-1-116

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 201 487-5800
 TELEX: 133521
 TELEFAX: 201 343-1684

INFORMATION FOR SEQ ID NO: 34:

SEQUENCE CHARACTERISTICS:
 LENGTH: 9 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: DNA synthetic probe
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 ; US-08-369-796-34

RESULT 15
 US-08-369-796-36/C
 ; Sequence 36, Application US/08369796
 ; Patent No. 5716622

GENERAL INFORMATION:
 APPLICANT: James E. Darnell, Jr.

APPLICANT: Zilong Wen
APPLICANT: Curt M. Horvath

APPLICANT: Zhong Zhou
TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL PROTEINS

TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS

NUMBER OF SEQUENCES: 39

CORRESPONDENCE ADDRESS:

ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US08/369,796
FILING DATE: 06-JAN-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-116

TELECOMMUNICATION INFORMATION:

TELEPHONE: 201 487-5800
TELEFAX: 201 343 1684
TELEX: 133521

INFORMATION FOR SEQ ID NO: 36:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: double

TOPOLOGY: linear
MOLECULE TYPE: DNA synthetic probe

HYPOTHETICAL: NO

ANTI-SENSE: NO

; US-08-369-796-36

Query Match 82.2% Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 1.9e+07;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 ttctttagaa 9
||| |||||
Db 9 TTCCGAGAA 1

Search completed: April 21, 2001, 13:12:32
Job time: 3545 sec

THIS PAGE BLANK (USPTO)

XX
PS Claim 7; Page 125; 135pp; English.
XX
CC The present oligonucleotide comprises a regulatory element
CC $T^x(N_x)AA$, where x is 4-7, and the regulatory element binds an
CC activated transcriptional regulatory protein in response to a
CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
CC spacer regulatory element can be used to detect the presence of
CC a transcriptional regulatory protein in a sample, and in assays
CC for (anti)agonists of gene transcription. The identified cpds.
CC may be used to treat cytokine-induced disease states, or to
CC ameliorate disease states caused by cytokine deficiency, e.g.
CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
XX
SQ Sequence 9 BP; 3 A; 2 C; 1 G; 3 T; 0 other;

Query Match	100.0%	Score 9;	DB 16;	Length 9;
Best Local Similarity	100.0%	Pred. No.	6.5e+07;	
Matches	9;	Conservative	0;	Mismatches 0;
Indels	0;	Gaps	0;	

OY 1 ttctggaa 9
Db 9 TCTGAGAA 1

RESULT 2
T41583/C
ID T41583 standard; DNA; 9 BP.
XX
AC T41583;
XX
DT 04-JUN-1997 (first entry)
XX
DE Cytokine activated STAT protein dependent DNA regulatory element.
XX
KW regulatory element; protein; cytokine; responsive; host cell;
KW transfection; agonist; antagonist; mediated; transcription;
modulation; STAT; STAT5; STAT6; signalling pathway; ss.
XX
OS Synthetic.
XX
PN W09630515-A1.
XX
PD 03-OCT-1996.
XX
PF 25-MAR-1996; 96WO-US04012.
XX
PR 27-MAR-1995; 95US-0410779.
XX
PA (LIGA-) LIGAND PHARM INC.
XX
PI Lamb IP, Seidel HM;
XX
DR WPI; 1998-541763/46;
XX
PT DNA constructs containing cytokine-responsive regulatory elements -
PT useful in assays for transcription-regulating proteins or gene
PT transcription agonists or antagonists
XX
PS Disclosure; Column 11; 58pp; English.
XX
CC V56842-v56976 and V61601-v61631 are oligonucleotides used in the
CC production of constructs comprising a cytokine-responsive regulatory
CC element linked to a promoter which is linked to a heterologous coding
CC sequence so that the coding sequence is under the transcriptional control
CC of the regulatory element and the promoter, where the regulatory element
CC has a nucleotide sequence selected from T $CNNNN$ A, T $NNNN$ A, and T $NCNNNT$
CC where N is A, T, C or G, and Y = 3 or 4. The constructs can be used to
CC detect or isolate transcription-regulating proteins, e.g. STAT proteins,
CC in a sample by contacting the sample with the construct so that the
CC protein binds to the regulatory element, and detecting or separating the
CC resulting complex. The cells can be used in screening assays for agonists
CC of gene transcription, in which the level of expression of the coding
CC sequence is measured in the presence and absence of a test compound or
CC in the presence of the corresponding cytokine.
XX
SQ Sequence 9 BP; 3 A; 2 C; 1 G; 3 T; 0 other;

CC cytokine modulators involved in the STAT5 and/or STAT6 protein
CC signalling pathway.
XX
Sequence 9 BP; 3 A; 2 C; 1 G; 3.T; 0 other;

Query Match	100.0%	Score 9;	DB 17;	Length 9;
Best Local Similarity	100.0%	Pred. No.	6.5e+07;	
Matches	9;	Conservative	0;	Mismatches 0;
Indels	0;	Gaps	0;	

OY 1 ttctggaa 9
Db 9 TCTGAGAA 1

RESULT 3
V56876/C
ID V56876 standard; DNA; 9 BP.
XX
AC V56876;
XX
DT 02-DEC-1998 (first entry)
XX
DE Regulatory element containing oligonucleotide #35.
XX
KW Cytokine-responsive regulatory; primer; promoter; detection; isolation;
KW transcriptional control; STAT protein; screening; agonist; ss.
XX
OS Synthetic.
XX
PN US5814517-A.
XX
PD 29-SEP-1998.
XX
PR 27-MAR-1995;
PR 14-APR-1994; 94US-0228935.
XX
PA (LIGA-) LIGAND PHARM INC.
XX
PI Lamb IP, Seidel HM;
XX
DR WPI; 1998-541763/46;
XX
PT DNA constructs containing cytokine-responsive regulatory elements -
PT useful in assays for transcription-regulating proteins or gene
PT transcription agonists or antagonists
XX
PS Disclosure; Column 11; 58pp; English.
XX
CC V56842-v56976 and V61601-v61631 are oligonucleotides used in the
CC production of constructs comprising a cytokine-responsive regulatory
CC element linked to a promoter which is linked to a heterologous coding
CC sequence so that the coding sequence is under the transcriptional control
CC of the regulatory element and the promoter, where the regulatory element
CC has a nucleotide sequence selected from T $CNNNN$ A, T $NNNN$ A, and T $NCNNNT$
CC where N is A, T, C or G, and Y = 3 or 4. The constructs can be used to
CC detect or isolate transcription-regulating proteins, e.g. STAT proteins,
CC in a sample by contacting the sample with the construct so that the
CC protein binds to the regulatory element, and detecting or separating the
CC resulting complex. The cells can be used in screening assays for agonists
CC of gene transcription, in which the level of expression of the coding
CC sequence is measured in the presence and absence of a test compound or
CC in the presence of the corresponding cytokine.
XX
SQ Sequence 9 BP; 3 A; 2 C; 1 G; 3 T; 0 other;

Query Match 100.0% score 9; DB 19; Length 9;
Best Local Similarity 100.0%; Pred. No. 6.5e+07;
Matches 9; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

QY 1 ttctggagaa 9
 |||||
 9 TCTGAGAA 1

RESULT 4
 X77642/C
 ID X77642 standard; DNA; 11 BP.
 XX
 KW Junction fragment; vector; simian immunodeficiency virus; SIV; gag;
 AC pol; vif; vpx; long terminal repeat; LTR; HIV-; env; tat; rev;
 XX nef; vpr; chimeric virus; replication competent; monkey; mandrill;
 DT macaque; disease progression; vaccine; epitope; immune response;
 XX envelope glycoprotein; cytotoxic T lymphocyte; ss.
 DE synthetic.

DE NIL active EGS 6.

XX
 KW External guide sequence; EGS; target mRNA; identification; diagnostic;
 XX inactivation; essential gene; therapy; ss.

OS Synthetic.

XX
 PN W09927135-A2.

XX
 PD 03-JUN-1999.

XX
 PF 20-NOV-1998; 98WO-US24854.

XX
 PR 30-MAR-1998; 98US-0079851.

PR 21-NOV-1997; 97US-0976220.

PA (INNO-) INNOVIR LAB INC.

XX
 PT Kindt TJ, Nilsen TW, Robertson HD;

XX
 DR WPI: 1999-357853/30.

PT Identifying and inhibiting functional nucleic acid molecules in
 XX cells

PS Example 3; Page 28; 58pp; English.

XX
 CC This invention describes a novel method allowing essential or functional
 CC genes to be rapidly identified and inactivated. The method is able to
 firstly identify most of the essential genes in an organism (i.e. a
 CC bacteria or a eukaryote) needed for survival, and secondly it provides
 CC for reducing or inactivating their expression. The method is able to
 identify functional oligonucleotide molecules able to be used as
 CC diagnostic reagents and therapeutics. The method provides a means for
 CC identifying essential genes whose sequence is known only as part of a
 CC genome with unknown function, as well as a means for identifying
 CC functional oligonucleotide molecules. The method involves the use of a
 CC nucleic acid molecule comprising (a) a first reporter gene encoding a
 CC fusion protein comprising a protein of interest (itself translated from
 CC an RNA of interest) and a reporter protein, a second reporter gene
 CC encoding a second reporter protein, and (c) a targeting gene encoding a
 CC functional oligonucleotide molecule such as an external guide sequence
 CC (EGS), a ribozyme or an antisense RNA and targeted to the RNA of interest
 CC at a site on the first reporter gene able to encode the RNA of interest.

SQ Sequence 11 BP; 4 A; 4 C; 1 G; 2 T; 0 other;

Query Match 88.9%; Score 8; DB 20; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+04;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ttctggagaa 9
 |||||
 9 TCTGAGAA 1

RESULT 5
 Q53424/C
 ID Q53424 standard; DNA; 9 BP.

XX
 XX 053424;
 AC XX
 XX DT 16-JUN-1994 (first entry)
 XX SIVmac/HIV-1 junction region #3.
 DE XX Junction fragment; vector; simian immunodeficiency virus; SIV; gag;
 KW pol; vif; vpx; long terminal repeat; LTR; HIV-; env; tat; rev;
 KW nef; vpr; chimeric virus; replication competent; monkey; mandrill;
 KW macaque; disease progression; vaccine; epitope; immune response;
 KW envelope glycoprotein; cytotoxic T lymphocyte; ss.
 XX OS synthetic.

XX
 PN W09324632-A.

XX
 PD 09-DEC-1993.

XX
 PF 20-MAY-1993; 93WO-US04814.

XX
 PR 22-MAY-1992; 92US-0887505.

XX
 PA (DAND) DANA FARBER CANCER INST INC.
 PA (HARD) HARVARD COLLEGE.

XX
 PI Haseltine WA, Letvin N, Li J, Sodroski J;

XX DR WPI: 1993-405823/50.

XX
 PT Hybrid SIV-HIV-1 viral vectors - used to provide animal models
 PT for HIV-1 infection or a therapeutic agents or in vaccines for
 HIV-1.

XX PS Disclosure; Fig 1C; 72pp; English.

CC The sequences given in Q53422-28 represent junction fragments which
 CC were used in the construction the vectors of the invention. These
 CC vectors contain a 5' DNA segment which contains a sufficient number
 CC of nucleotides corresponding to a simian immunodeficiency virus (SIV)
 CC genome to encode a functional gag, pol, vif and vpx protein and has
 CC a SIV long terminal repeat (LTR), and a 3' DNA segment which contains
 CC a sufficient number of nucleotides corresponding to at least one
 CC HIV-1 genome to encode a functional HIV-1 env, tat and rev protein
 CC and a sufficient number of nucleotides corresponding to a SIV genome
 CC to encode a functional nef protein and has a SIV LTR. The vector
 CC further comprises a sufficient number of nucleotides corresponding to
 CC the SIV genome to encode a functional SIV vpr protein. Vectors such
 CC as these produce chimeric viruses containing HIV-1 components. As a
 CC result of transfecting cells with these vectors, replication competent
 CC viruses that are infectious in animal systems such as monkeys, eg.
 CC mandrills, macaques, etc. can be produced. The vectors can be used for
 CC creating an animal model for studying disease progression by HIV-1,
 CC for screening for compounds exhibiting anti-HIV activity, for screening
 CC for a vaccine against HIV infection and for determining the specific
 CC epitopes of a HIV-1 envelope glycoprotein recognised by cytotoxic T
 CC lymphocytes. They can also be used to boost immune response in a HIV
 CC infected individual or as a vaccine to prevent infection.

SQ Sequence 9 BP; 3 A; 1 C; 1 G; 4 T; 0 other;

Query Match 82.2%; Score 7.4; DB 14; Length 9;
 Best Local Similarity 88.9%; Pred. No. 6.5e+07;
 Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ttctggagaa 9
 |||||
 9 TTCGAAAA 1

DB 9 TTCGAAAA 1

PS
XX Disclosure; Column 11; 58pp; English.

CC V56842-V56976 and V61601-V61631 are oligonucleotides used in the
CC production of constructs comprising a cytokine-responsive regulatory
CC element linked to a promoter which is linked to a heterologous coding
CC sequence so that the coding sequence is under the transcriptional control
CC of the regulatory element and the promoter, where the regulatory element
CC has a nucleotide sequence selected from TT_NNNRA, T_YAN_YRA, and T_CNY_{TA}
CC where N is A, T, C or G, and Y = 3 or 4. The constructs can be used to
CC detect or isolate transcription-regulating proteins, e.g., STAT proteins,
CC in a sample by contacting the sample with the construct so that the
CC protein binds to the regulatory element, and detecting or separating the
CC resulting complex. The cells can be used in screening assays for agonists
CC of gene transcription, in which the level of expression of the coding
CC sequence is measured in the presence and absence of a test compound or
CC in the presence of the corresponding cytokine.
XX

SO Sequence 9 BP; 3 A; 2 C; 1 G; 3 T; 0 other;

Query	Match	Score	DB	Length	Matches	Similarity	Pred.	No.	Mismatches	Indels	Caps	0;
Qy	1 ttctggaa	82.2%	19	9	8;	88.9%	0;	5e+07	1;	0;	0;	
Db	1 ttctcagaa											

Search completed: April 21, 2001, 13:14:35
Job time: 3601 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

On nucleic - nucleic search, using sw model

Run on: April 21, 2001, 11:42:58 ; Search time 1240.49 Seconds

(without alignments)
44.677 Million cell updates/sec

Title: SHORT
Perfect score: 9
Sequence: 1 ttctggaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1283235 seqs, 3078962356 residues

Total number of hits satisfying chosen parameters: 15938

Minimum DB seq length: 0
Maximum DB seq length: 12

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1:	gb_bal:*
2:	gb_ba2:*
3:	gb_ba3:*
4:	gb_in1:*
5:	gb_in2:*
6:	gb_in3:*
7:	gb_om:*
8:	gb_ov:*
9:	gb_pati:*
10:	gb_pat2:*
11:	gb_ph:*
12:	gb_pl1:*
13:	gb_p2:*
14:	gb_p3:*
15:	gb_p4:*
16:	gb_bp1:*
17:	gb_ba:*
18:	em_fun:*
19:	em_htgo_hum:*
20:	em_htgo_inv:*
21:	em_htgo_rid:*
22:	em_htg_hum1:*
23:	em_htg_hum2:*
24:	em_htg_hum3:*
25:	em_htgo_hum4:*
26:	em_htgo_hums:*
27:	em_htg_hum7:*
28:	em_htg_hum:*
29:	em_htg_hum:*
30:	em_htg_inv1:*
31:	em_htg_inv2:*
32:	em_htg_other:*
33:	em_htg_rid:*
34:	em_hum:*
35:	em_hum2:*
36:	em_hum3:*
37:	em_hum4:*
38:	em_hum5:*
39:	em_hum6:*
40:	em_hum7:*
41:	em_in:*
42:	em_in:*
43:	em_or:*

44: em_ov:*
 45: em_pat:*
 46: em_ph:*
 47: em_pl:*
 48: em_ro:*
 49: em_sts:*
 50: em_sy:*
 51: em_un:*
 52: em_v1:*
 53: gb_sts2:*
 54: gb_sts3:*
 55: gb_sy:*
 56: gb_sy:*
 57: gb_un:*
 58: gb_v1:*
 59: gb_v2:*
 60: gb_htc1:*
 61: gb_htc2:*
 62: gb_htc3:*
 63: gb_htc4:*
 64: gb_htc5:*
 65: gb_htc6:*
 66: gb_htc7:*
 67: gb_htc8:*
 68: gb_htc9:*
 69: gb_htc10:*
 70: gb_htc11:*
 71: gb_htc12:*
 72: gb_htc13:*
 73: gb_htc14:*
 74: gb_htc15:*
 75: gb_htc16:*
 76: gb_htc17:*
 77: gb_htc18:*
 78: gb_htc19:*
 79: gb_htc20:*
 80: gb_htc21:*
 81: gb_htc22:*
 82: gb_htc23:*
 83: gb_htc24:*
 84: gb_htc25:*
 85: gb_pr1:*
 86: gb_pr2:*
 87: gb_pr3:*
 88: gb_pr4:*
 89: gb_pr5:*
 90: gb_pr6:*
 91: gb_pr7:*
 92: gb_pr8:*
 93: gb_pr9:*
 94: gb_rid:*
 95: gb_rid:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

%
Result No. Score Match Length DB ID Description

C 1 7.4 82.2 9 AX041991 A X041991 Sequence
C 2 7.4 82.2 10 9 AR043683 A R043683 Sequence
C 3 7.4 82.2 10 9 AR043683 A R043683 Sequence
C 4 7.4 82.2 11 9 AR097294 A R097294 Sequence
C 5 7.4 82.2 11 9 AX063653 A X063653 Sequence
C 6 7.4 82.2 11 9 AX063656 A X063656 Sequence
C 7 7.4 82.2 11 10 I39722 Sequence 9 I39722 Sequence 9
C 8 7.4 82.2 11 10 I55839 Sequence 9 I55839 Sequence 9
C 9 7.4 82.2 12 93 S75371 S75371 beta-hexosa
C 10 7.4 82.2 12 93 S75371 beta-hexosa
C 11 7.4 82.2 12 93 S75371 beta-hexosa
C 12 7.4 82.2 12 93 S75371 beta-hexosa
C 13 7.4 82.2 12 93 S75371 beta-hexosa
C 14 7.4 82.2 12 93 S75371 beta-hexosa
C 15 7.4 82.2 12 93 S75371 beta-hexosa
C 16 7.4 82.2 12 93 S75371 beta-hexosa
C 17 7.4 82.2 12 93 S75371 beta-hexosa
C 18 7.4 82.2 12 93 S75371 beta-hexosa
C 19 7.4 82.2 12 93 S75371 beta-hexosa
C 20 7.4 82.2 12 93 S75371 beta-hexosa
C 21 7.4 82.2 12 93 S75371 beta-hexosa
C 22 7.4 82.2 12 93 S75371 beta-hexosa
C 23 7.4 82.2 12 93 S75371 beta-hexosa
C 24 7.4 82.2 12 93 S75371 beta-hexosa
C 25 7.4 82.2 12 93 S75371 beta-hexosa
C 26 7.4 82.2 12 93 S75371 beta-hexosa
C 27 7.4 82.2 12 93 S75371 beta-hexosa
C 28 7.4 82.2 12 93 S75371 beta-hexosa
C 29 7.4 82.2 12 93 S75371 beta-hexosa
C 30 7.4 82.2 12 93 S75371 beta-hexosa
C 31 7.4 82.2 12 93 S75371 beta-hexosa
C 32 7.4 82.2 12 93 S75371 beta-hexosa
C 33 7.4 82.2 12 93 S75371 beta-hexosa
C 34 7.4 82.2 12 93 S75371 beta-hexosa
C 35 7.4 82.2 12 93 S75371 beta-hexosa
C 36 7.4 82.2 12 93 S75371 beta-hexosa
C 37 7.4 82.2 12 93 S75371 beta-hexosa
C 38 7.4 82.2 12 93 S75371 beta-hexosa
C 39 7.4 82.2 12 93 S75371 beta-hexosa
C 40 7.4 82.2 12 93 S75371 beta-hexosa
C 41 7.4 82.2 12 93 S75371 beta-hexosa
C 42 7.4 82.2 12 93 S75371 beta-hexosa
C 43 7.4 82.2 12 93 S75371 beta-hexosa
C 44 7.4 82.2 12 93 S75371 beta-hexosa
C 45 7.4 82.2 12 93 S75371 beta-hexosa
C 46 7.4 82.2 12 93 S75371 beta-hexosa
C 47 7.4 82.2 12 93 S75371 beta-hexosa
C 48 7.4 82.2 12 93 S75371 beta-hexosa
C 49 7.4 82.2 12 93 S75371 beta-hexosa
C 50 7.4 82.2 12 93 S75371 beta-hexosa
C 51 7.4 82.2 12 93 S75371 beta-hexosa
C 52 7.4 82.2 12 93 S75371 beta-hexosa
C 53 7.4 82.2 12 93 S75371 beta-hexosa
C 54 7.4 82.2 12 93 S75371 beta-hexosa
C 55 7.4 82.2 12 93 S75371 beta-hexosa
C 56 7.4 82.2 12 93 S75371 beta-hexosa
C 57 7.4 82.2 12 93 S75371 beta-hexosa
C 58 7.4 82.2 12 93 S75371 beta-hexosa
C 59 7.4 82.2 12 93 S75371 beta-hexosa
C 60 7.4 82.2 12 93 S75371 beta-hexosa
C 61 7.4 82.2 12 93 S75371 beta-hexosa
C 62 7.4 82.2 12 93 S75371 beta-hexosa
C 63 7.4 82.2 12 93 S75371 beta-hexosa
C 64 7.4 82.2 12 93 S75371 beta-hexosa
C 65 7.4 82.2 12 93 S75371 beta-hexosa
C 66 7.4 82.2 12 93 S75371 beta-hexosa
C 67 7.4 82.2 12 93 S75371 beta-hexosa
C 68 7.4 82.2 12 93 S75371 beta-hexosa
C 69 7.4 82.2 12 93 S75371 beta-hexosa
C 70 7.4 82.2 12 93 S75371 beta-hexosa
C 71 7.4 82.2 12 93 S75371 beta-hexosa
C 72 7.4 82.2 12 93 S75371 beta-hexosa
C 73 7.4 82.2 12 93 S75371 beta-hexosa
C 74 7.4 82.2 12 93 S75371 beta-hexosa
C 75 7.4 82.2 12 93 S75371 beta-hexosa
C 76 7.4 82.2 12 93 S75371 beta-hexosa
C 77 7.4 82.2 12 93 S75371 beta-hexosa
C 78 7.4 82.2 12 93 S75371 beta-hexosa
C 79 7.4 82.2 12 93 S75371 beta-hexosa
C 80 7.4 82.2 12 93 S75371 beta-hexosa
C 81 7.4 82.2 12 93 S75371 beta-hexosa
C 82 7.4 82.2 12 93 S75371 beta-hexosa
C 83 7.4 82.2 12 93 S75371 beta-hexosa
C 84 7.4 82.2 12 93 S75371 beta-hexosa
C 85 7.4 82.2 12 93 S75371 beta-hexosa
C 86 7.4 82.2 12 93 S75371 beta-hexosa
C 87 7.4 82.2 12 93 S75371 beta-hexosa
C 88 7.4 82.2 12 93 S75371 beta-hexosa
C 89 7.4 82.2 12 93 S75371 beta-hexosa
C 90 7.4 82.2 12 93 S75371 beta-hexosa
C 91 7.4 82.2 12 93 S75371 beta-hexosa
C 92 7.4 82.2 12 93 S75371 beta-hexosa
C 93 7.4 82.2 12 93 S75371 beta-hexosa
C 94 7.4 82.2 12 93 S75371 beta-hexosa
C 95 7.4 82.2 12 93 S75371 beta-hexosa

	BASE COUNT	5 a	2 c	1 g	4 t
QY	1 ttctggaa 9 				
Db	2 T ^m TGGAA 10				
RESULT 9					
LOCUS S75371	12 bp mRNA	PRT	07-MAY-1993		
DEFINITION beta-hexosaminidase A {exon 8}	[human, mRNA Partial Mutant, 12 nt].				
ACCESSION S75371.1	GI:241964				
KEYWORDS	human.				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE 1 (bases 1 to 12)	Akli,S., Cheilly,J., Lacorte,J.M., Poenaru,L. and Kahn,A.				
TITLE	Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of PCR-amplified cDNA fragments				
JOURNAL	Genomics 11 (1), 124-134 (1991)				
MEDLINE	92112203				
REMARK	GenBank Staff at the National Library of Medicine created this entry [NCBI gibbsq 75371] from the original journal article. This sequence comes from Figure 4.D.				
FEATURES source	Location/Qualifiers				
gene	1..12				
	/organism="Homo sapiens"				
	1..12				
	/db_xref="taxon:9606"				
	/partial				
	5 a 2 c				
BASE COUNT					
ORIGIN					
Query Match Best Local Similarity 88.9%; Pred. No. 1.1e+05; Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	1 ttctggaa 9 				
Db	4 TTCTAGAA 12				
RESULT 10					
LOCUS S75371	12 bp mRNA	PRT	07-MAY-1993		
DEFINITION beta-hexosaminidase A {exon 8} [human, mRNA Partial Mutant, 12 nt].					
ACCESSION S75371					
VERSION S75371.1	GI:241964				
KEYWORDS	human.				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE 1 (bases 1 to 12)	Akli,S., Cheilly,J., Lacorte,J.M., Poenaru,L. and Kahn,A.				
TITLE	Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of PCR-amplified cDNA fragments				
JOURNAL	Genomics 11 (1), 124-134 (1991)				
MEDLINE	92112203				
REMARK	GenBank Staff at the National Library of Medicine created this entry [NCBI gibbsq 75371] from the original journal article. This sequence comes from Figure 4.D.				
FEATURES source	Location/Qualifiers				
gene	1..12				
	/organism="Homo sapiens"				
	/db_xref="taxon:9606"				
	1..12				
	/partial				
	/gene="beta-hexosaminidase A"				
BASE COUNT					
ORIGIN					
Query Match Best Local Similarity 88.9%; Pred. No. 1.1e+05; Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	1 ttctggaa 9 				
Db	12 TTCTAGAA 4				
RESULT 11					
LOCUS AR101594	8 bp DNA	PAT	14-FEB-2001		
DEFINITION Sequence 516 from Patent US 6083695.					
ACCESSION AR101594					
VERSION AR101594.1	GI:12812392				
KEYWORDS	Unknown.				
SOURCE	Unclassified.				
REFERENCE 1 (bases 1 to 8)	Hardin,S,Houck, Honayouli,R. and Hardin,P.Eric.				
AUTHORS	Optimized primer library for gene sequencing and method of using same				
TITLE	Patent: US 6083695-A 516 04-JUL-2000;				
JOURNAL	Location/Qualifiers				
FEATURES source	1..8				
	/organism="unknown"				
BASE COUNT	2 a 2 c 2 g 2 t				
ORIGIN					
Query Match Best Local Similarity 100.0%; Pred. No. 1.8e+09; Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	2 ttctggaa 8 				
Db	1 TTCTGAGA 7				
RESULT 12					
LOCUS A41392/c	10 bp DNA	PAT	05-MAR-1997		
DEFINITION Sequence 18 from Patent WO9426928.					
ACCESSION A41392					
VERSION A41392.1	GI:2297111				
KEYWORDS					
SOURCE	synthetic construct.				
ORGANISM	synthetic construct.				
REFERENCE 1 (bases 1 to 10)	artificial sequence.				
AUTHORS	Strauss,M. and Bauer,D.				
TITLE	COMPLEX DIAGNOSTIC AGENT OF GENETIC EXPRESSION AND MEDICAL				
	DIAGNOSIS AND GENE ISOLATION PROCESS USING SAID DIAGNOSTIC AGENT				
JOURNAL	Patent: WO 9426928-A 18 24-NOV-1994;				
COMMENT	MAX PLANCK GESELLSCHAFT (DE)				
FEATURES source	Other publication DE 4317414 940421.				
	1..10				
	/organism="synthetic construct"				
BASE COUNT	3 a 3 c 2 g 2 t				
ORIGIN					
Query Match Best Local Similarity 100.0%; Pred. No. 2.4e+06; Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	77.8% score 7; DB 9; Length 10;				
Db	/ab_xref="taxon:9606"				
gene	1..12				
	/partial				
	/gene="beta-hexosaminidase A"				

QY 2 tctgaga 8
|||||||
Db 9 TCTGAGA 3

RESULT 13
A24764/c
DEFINITION A24764 11 bp DNA
ACCESSION A24764
VERSION A24764.1 GI:833668
KEYWORDS synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 12)
AUTHORS Hudson,P.J., Haley,J.D., Niall,H.D. and Shine,J.
TITLE Molecular cloning and characterization of the gene sequence coding
for porcine relaxin
PATENT EP 0086649-A 8 24-AUG-1983;
JOURNAL HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE
FEATURES Location/Qualifiers
SOURCE /organism="synthetic construct"
/db_xref="taxon:32630"
TITLE MODIFIED GENES AND THEIR EXPRESSION IN PLANT CELLS
JOURNAL Patent: WO 9309218-A 4 13-MAY-1993;
FEATURES Location/Qualifiers
source 1. 11
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 3 a 3 c 2 g 3 t
ORIGIN

Query Match 77.8%; Score 7; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.3e+06;
Matches 7; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

QY 3 ctgaaaa 9
|||||||
Db 11 CTGAGAA 5

RESULT 14
AR074369/c
LOCUS AR074369 11 bp DNA
DEFINITION Sequence 4 from patent US 5952547.
ACCESSION AR074369
VERSION AR074369.1 GI:10001124
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1. (bases 1 to 11)
AUTHORS Cornelissen,M., Soetaert,P., Stann,M., Dockx,J. and Van Aarssen,R.
TITLE Modified *Bacillus thuringiensis* genes with improved expression in
plant cells, methods of production on and use
JOURNAL Patent: US 5952547-A 4 14-SEP-1999;
FEATURES Location/Qualifiers
source 1. 11
/organism="unknown"
BASE COUNT 3 a 3 c 2 g 3 t
ORIGIN

Query Match 77.8%; Score 7; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.3e+06;
Matches 7; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

RESULT 15
A06058
LOCUS A06058 12 bp DNA
DEFINITION Synthetic primer 476-487.
ACCESSION A06058
VERSION A00058.1 GI:411190

Query Match 77.8%; Score 7; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.3e+06;
Matches 7; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

QY 3 ctgaaaa 9
|||||||
Db 11 CTGAGAA 5

Query Match 77.8%; Score 7; DB 9; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.3e+06;
Matches 7; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

QY 2 tctgaga 8
|||||||
Db 3 TCTGAGA 9

Search completed: April 21, 2001, 13:07:39
Job time: 5081 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
 Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on : April 21, 2001, 11:14:44 ; Search time 1100.03 Seconds
 (without alignments)
 1.196 Million cell updates/sec

Searched: 9623517 seqs, 73081774 residues

Total number of hits satisfying chosen parameters: 308

Minimum DB seq length: 0

Maximum DB seq length: 12

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database :	EST:*
1:	gb_est1:*
2:	gb_est2:*
3:	gb_est3:*
4:	gb_est4:*
5:	gb_est5:*
6:	gb_est6:*
7:	gb_est7:*
8:	gb_est8:*
9:	gb_est9:*
10:	gb_est10:*
11:	gb_est11:*
12:	gb_est12:*
13:	gb_est13:*
14:	gb_est14:*
15:	gb_est15:*
16:	gb_est16:*
17:	gb_est17:*
18:	gb_est18:*
19:	gb_est19:*
20:	gb_est20:*
21:	gb_est21:*
22:	gb_est22:*
23:	gb_est23:*
24:	gb_est24:*
25:	gb_est25:*
26:	gb_est26:*
27:	gb_est27:*
28:	gb_est28:*
29:	gb_est29:*
30:	gb_est30:*
31:	gb_est31:*
32:	gb_est32:*
33:	gb_est33:*
34:	gb_est34:*
35:	gb_est35:*
36:	gb_est36:*
37:	gb_est37:*
38:	gb_est38:*
39:	gb_est39:*
40:	gb_est40:*
41:	gb_est41:*
42:	gb_est42:*
43:	gb_est43:*
44:	gb_est44:*
45:	gb_est45:*
46:	gb_est46:*
47:	gb_est47:*
48:	gb_est48:*
49:	gb_est49:*
50:	gb_est50:*
51:	gb_est51:*
52:	gb_est52:*
53:	gb_est53:*
54:	gb_est54:*
55:	gb_est55:*
56:	gb_est56:*
57:	gb_est57:*
58:	gb_est58:*
59:	gb_est59:*
60:	gb_est60:*
61:	gb_est61:*
62:	gb_est62:*
63:	gb_est63:*
64:	gb_est64:*
65:	gb_est65:*
66:	gb_est66:*
67:	gb_est67:*
68:	gb_est68:*
69:	gb_est69:*
70:	gb_est70:*
71:	gb_est71:*
72:	gb_est72:*
73:	gb_est73:*
74:	gb_est74:*
75:	gb_est75:*
76:	gb_est76:*
77:	gb_est77:*
78:	gb_est78:*
79:	gb_est79:*
80:	gb_est80:*
81:	gb_est81:*
82:	gb_est82:*
83:	gb_est83:*
84:	gb_est84:*
85:	gb_est85:*
86:	gb_est86:*
87:	gb_est87:*
88:	gb_est88:*
89:	gb_est89:*
90:	gb_est90:*
91:	gb_est91:*
92:	gb_est92:*
93:	gb_est93:*
94:	gb_est94:*
95:	gb_est95:*
96:	gb_est96:*
97:	gb_est97:*
98:	gb_est98:*
99:	gb_est99:*
100:	gb_est100:*
101:	gb_est101:*
102:	gb_est102:*
103:	gb_est103:*
104:	gb_est104:*
105:	gb_est105:*
106:	gb_est106:*
107:	gb_est107:*
108:	gb_est108:*
109:	gb_est109:*
110:	gb_est110:*
111:	gb_est111:*
112:	gb_est112:*
113:	gb_est113:*
114:	gb_est114:*
115:	gb_est115:*
116:	gb_est116:*

```

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est75:*
137: gb_est76:*
138: gb_est77:*
139: gb_est78:*
140: gb_est79:*
141: gb_est80:*
142: gb_est81:*
143: gb_est82:*
144: gb_est83:*
145: gb_est84:*
146: gb_est85:*
147: gb_est86:*
148: gb_est87:*
149: gb_est88:*
150: gb_est89:*
151: gb_est90:*
152: gb_est99:*
153: gb_est100:*
154: gb_est101:*
155: gb_est102:*
156: gb_est103:*
157: gb_est104:*
158: gb_est105:*
159: gb_est106:*
160: gb_est107:*
161: gb_est108:*
162: gb_est109:*
163: gb_est110:*
164: gb_est111:*
165: gb_est112:*
166: gb_est113:*
167: gb_est114:*
168: gb_est91:*
169: gb_est92:*
170: gb_est93:*
171: gb_est94:*
172: gb_est95:*
173: gb_est96:*
174: gb_est97:*
175: gb_est98:*
176: em_gss_fun:*
177: em_gss_hum1:*
178: em_gss_hum2:*
179: em_gss_hum3:*
180: em_gss_hum4:*
181: em_gss_hum5:*
182: em_gss_hum6:*
183: em_gss_hum7:*
184: em_gss_hum8:*
185: em_gss_hum9:*
186: em_gss_inv1:*
187: em_gss_inv2:*
188: em_gss_inv3:*
189: em_gss_other:*
190: em_gss_pnl1:*
191: em_gss_pnl2:*
192: em_gss_pro:*
193: em_gss_rcl1:*
194: em_gss_rcl2:*
195: em_gss_rcl3:*
196: em_gss_rcl4:*
197: em_gss_rcl5:*
198: em_gss_vrt1:*
199: em_gss_vrt2:*
200: em_gss_vrt3:*
201: gb_gss1:*
202: gb_gss2:*
203: gb_gss3:*
204: gb_gss4:*
205: gb_gss5:*
206: gb_gss6:*
207: gb_gss7:*
208: gb_gss8:*
209: gb_gss9:*
210: gb_gss10:*
211: gb_gss11:*
212: gb_gss12:*
213: gb_gss13:*
214: gb_gss14:*
215: gb_gss15:*
216: gb_gss16:*
217: gb_gss17:*
218: gb_gss18:*
219: gb_gss19:*
220: gb_gss20:*
221: gb_gss21:*
222: gb_gss22:*
223: gb_gss23:*
224: gb_gss24:*
225: gb_gss25:*
226: gb_gss26:*
227: gb_gss27:*
228: gb_gss28:*
229: gb_gss29:*
230: gb_gss30:*
231: gb_gss31:*
232: gb_gss32:*
233: gb_gss33:*
234: gb_gss34:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Length	DB ID	Description
1	5.4	60_0	12	113	AW250557 281633.5
2	4.8	53_3	11	60	HSM007328
3	4.8	53_3	11	60	HSM007344
4	4.8	53_3	11	60	HSM007376
5	4.4	48_9	11	60	HSM007328
6	4.4	48_9	11	60	HSM007344
7	4.4	48_9	11	60	HSM007376
8	4.4	48_9	11	113	AW250935
9	4.4	48_9	12	60	HSM007404
10	4.4	48_9	12	60	HSM007404
11	4.4	5	213	AQ09961	GSSTrc0795
12	4	5	213	AQ09961	GSSTrc0795
13	4	9	9	HSM008038	
14	4	11	112	AW247612	
15	4	11	112	AW247612	
16	4	11	113	AW250935	
17	4	12	105	AL047587	KR2P586G
18	4	12	105	AL047587	KR2P586G
3..8	42..2	11	206	AQ445580	GSSTrc0040

CC sequencing consortium of the German Genome Project.
 CC No s1 sequence available
 CC This clone is available at the RZPD in Berlin
 CC Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059 Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de

XX	Key	Location/Qualifiers
FH	source	1..11 /ab_xref="taxon:9606" /organism="Homo sapiens" /clone_id="DKFZp434G1721" /clone_lib="434 (synonym: htes3)". Vector pSPORT1; host DH10B; sites NotI + SalI" /dev_stage="adult" /tissue_type="testis"
XX	SQ	Sequence 11 BP; 2 A; 1 C; 3 G; 5 T; 0 other;

Query Match 48.9%; Score 4.4; DB 60; Length 11;
 Best Local Similarity 83.3%; Pred. No. 8e+07; ID HSM007376 standard; RNA; EST; 11 BP.

QY	1 ttctgta 6
Db	3 TTCGGA 8

XX

RESULT 7	Score 4.4; DB 60; Length 11;	
DT	12-MAR-1999 (Rel. 59, Last updated, Version 1)	
XX	Homo sapiens mRNA; EST DKFZp434H0321_r1 (from clone DKFZp434H0321)	
DE	EST; expressed sequence tag.	
XX	OS Homo sapiens (human)	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
XX	RN [1]	
RP	1..11	
RA	Blum H., Bauersachs S., Mewes W., Gassenhuber J., Wiemann S.;	
RT	; Submitted (12-MAR-1999) to the EMBL/GenBank/DBJ databases.	
XX	RL Blum H., Bauersachs S., Mewes W., Gassenhuber J., Wiemann S.; Submitted (12-MAR-1999) to the EMBL/GenBank/DBJ databases.	
CC	clone from S. Wiemann, sequenced by LMU within the cDNA sequencing consortium of the German Genome Project	
CC	No s1 sequence available	
CC	This clone is available at the RZPD in Berlin	
CC	Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059 Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de	
XX	Key Location/Qualifiers	
FH	source	1..11 /ab_xref="taxon:9606" /organism="Homo sapiens" /clone_id="DKFZp434G1721" /clone_lib="434 (synonym: htes3)". Vector pSPORT1; host DH10B; sites NotI + SalI" /dev_stage="adult" /tissue_type="testis"
XX	SQ	Sequence 11 BP; 2 A; 1 C; 3 G; 5 T; 0 other;

Query Match 48.9%; Score 4.4; DB 60; Length 11;
 Best Local Similarity 83.3%; Pred. No. 8e+07; ID HSM007376 standard; RNA; EST; 11 BP.

QY	1 ttctgta 6
Db	3 TTCGGA 8

XX

RESULT 8	Score 4.4; DB 60; Length 11;
AW250935	AW250935 LOCUS DEFINITION AW250935_3 prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2821359 3', mRNA sequence.

ACCESSION	AW50935	VERSION	KW
ID	HSM007404	EST.	XX
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; human.	SOURCE	EST.
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	ORGANISM	Homo sapiens
TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)	JOURNAL	NIH-MGC http://mgc.ncbi.nlm.nih.gov/.
COMMENT	Unpublished (1999) Other_ESRs: 2821359, Sprime Contact: Robert Strausberg, Ph.D. Tel: (301) 496-1500 Email: Robert.Strausberg@nih.gov		
Tissue	Procurement: DCTP/DTP CDNA Library Preparation: Linq	Procurement:	
Score	Hong/Rubin Laboratory CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNU) DNA Sequencing by: Berkeley MGC sequencing project. Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNU at: www.bionl.lnl.gov/biorp/image.html Base Calling / Quality Trimming: cross_match from University of Washington Genome Center PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley Drosophila Genome Project. University of Washington Genome Center: http://www.genome.washington.edu Low Quality Sequence: 11 contiguous PHRED high quality bases following vector sequence. Very Low Quality Sequence: Trace file contained 11 contiguous distinct peaks following vector sequence.	Project:	
Peak	PLCM6 row: J column: 16 High quality sequence stop: 11.		
FEATURES	Location/Qualifiers		
Source	1. 11 <organism="Homo sapiens" <db_xref="taxon:9606" <clone="IMAGE:2821159" <clone_lib="NIH-MGC_7" <tissue_type="Small cell carcinoma" <cell_line="MGCC" <lab_host="DH10B (phage-resistant)" <note="Organ: lung; Vector: pORB7; Site_1: XbaI; Site_2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XbaI sites using the following 5'- adaptor: GGCAGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-CDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."		
ORIGIN	BASE COUNT	5 a 1 c 4 g 1 t	
RESULT	9		
Query Match	48.9%	Score	4.4;
Best Local Similarity	83.3%	Pred. No.	8e+07;
Matches	5;	Mismatches	1;
Conservative	0;	Indels	0;
		Gaps	0;
OY	3 ctgaga 8	QY	1 ttctcta 6
Db	4 CAGAGA 9	Db	2 TTGGA 7
ORIGIN		RESULT	10
SV		HSM007404/C	
XX		ID	HSM007404
AC		XX	standard; RNA; EST; 12 BP.
XX		AL042554;	
SV		SV	AL042554.1
XX		DT	12-MAR-1999 (Rel. 59, Created)
DT		DT	12-MAR-1999 (Rel. 59, Last updated, version 1)
XX		XX	
DE		Homo sapiens mRNA; EST DRFP3410921_r1 (from clone DRFP3410921)	
KW		KW	EST; expressed sequence tag.
OS		OS	Homo sapiens (human)
OC		OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Butheria; Primates; Catarrhini; Hominidae; Homo.
XX		XX	
RN		RN	[1]
RP		RP	1-12
RA		RA	Blum H., Bauersachs S., Mewes W., Gassnerhuber J., Wiemann S.;
RT		RT	;
RL		RL	Submitted (12-MAR-1999) to the EMBL/GenBank/DDBJ databases.
XL		XL	NIPS, Am Klopferspitz 18a D-82152 Martinsried, GERMANY
CC		CC	Clone from S. Wiemann, sequenced by LMU within the CDNA sequencing consortium of the German Genome Project
CC		CC	No sl sequence available

Plate: L1CM6 row: J column: 16
 High quality sequence stop: 11.
 Location/Qualifiers
 source 1..11
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:821359"
 /clone_1_id="NTH:MGC:7"
 /tissue_type="small cell carcinoma"
 /cell_line="MGC3"
 /lab_host="DH10B (phage-resistant)"
 /note="Organ: lung; vector: pOMB7; site_1: XbaI; site_2:
 EcoRI; cDNA made by oligo-dT priming. Directionally
 cloned into EcoRI/XbaI sites using the following 5'
 adapter: GCAACAG(G). Size-selected >500bp for average
 insert size 1.8kb. Library constructed by Ling Hong in
 the laboratory of Gerald M. Rubin (University of
 California, Berkeley) using ZAP-cDNA synthesis kit
 (Stratagene) and superscript II RT (Life Technologies)."
 5 a 1 c 1 t 1 g 4 9 1 t
 BASE COUNT ORIGIN

Query Match 44 4%; Score 4; DB 113; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+08;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	2	TCTG	5
DB	7	TCTG	4

Search completed: April 21, 2001, 12:34:38
 Job time: 4794 sec

THIS PAGE BLANK (USPTO)